Cingulate Inc (CING)

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26June 4, 2026 4:48 PM
Newsfile Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. The FDA issued a Complete Response Letter for the CTx-1301 NDA focused on specific CMC information requests, with no current clinical safety or efficacy concerns identified. In our view, the key read-through is timing rather than product viability, as the path forward now depends on completing the requested CMC work, resubmitting to FDA, and moving through the next review cycle. Importantly, Cingulate disclosed nearly $30M of cash on hand, which management believes is sufficient to address the FDA's requests, execute the resubmission process, and continue pre-commercial activities into 2027. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Balance sheet now supports execution. With C$51.1M in cash and C$51.0M of equity, American Tungsten is funded to advance IMA without near-term capital pressure. IMA is moving from concept to execution. Q1 spend of C$4.8M on exploration/evaluation shows capital is being deployed directly into underground access, drilling, assays, and field work. Uplist improves investability. The move to the TSXV on May 29, 2026 expands market visibility and should improve institutional access as the story matures. Click image above to view full announcement. About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300273 Original: Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Management has been oddly quiet all day. Maybe announce the news AH.

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25April 6, 2026 4:34 PM
NewsfileDallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance. The NDA remains under FDA review under the 505(b)(2) pathway, and recent financing, IP progress, and commercial buildout efforts remain supportive of the broader investment thesis. Importantly, following the $12M PIPE completed in February 2026, the Company has a pro forma cash balance of approximately ~$23M, which we estimate provides runway into late 2026. Combined with ongoing access to capital through its ATM and ELOC facilities, we believe Cingulate is positioned to fund ongoing regulatory and manufacturing activities as it works toward resolution of remaining CMC items. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: FDA feedback limited to manufacturing/CMC; no safety or efficacy concerns, positioning remaining work as addressable process validation rather than clinical risk. Regulatory timing may shift, but approval remains likely; delay driven by manufacturing validation, not fundamental issues with product profile. Large ADHD market opportunity: ~1% share implies ~$250M revenue potential for CTx-1301, primarily targeting the booster-dose segment, as disclosed by the Company. Click image above to view full announcement. About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291352
Original: Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

$4 bottom 

Time to CING again ...stay tuned

You must be indeed be High, on hot air in Head!!!

You are responding to a post where I congratulated investors after an apparent short squeeze. Do you have a problem with investors winning over financial terrorists?

As you have been already BURNED by LIFE, DrHIGH!!! What a trash of a being....

Flipped it already 90% of these stocks reverse split money printing scams. Trade technicals 

its a scam

$4.67 Keep an eye ADHD anxiety low floater 

CING under $10

Trash. Told you. Dilute. Get ready for class action.

STREAM DECK ELGATO: Thanks!! (Never heard of it!)

THAT WAS CORRECT*****TOMORROW WILL BE A BETTER DAY. CHECK OUT "STREAM DECK ELGATO' FOR QUICK FAST IN AND OUT IF U HAVE NOT ALREADY. JUST FOUND OUT ABOUT IT

Indeed, Dude. And on that note, I would estimate --- right after I tossed Reena969's @INM pick into my 'E-Turd' search box, & saw it up in the Pre-M today by 145% --- that I would have had circa 15-minutes to buy it, & then dump it, when it (rapidly) hit about 500% up. And, if YOU are on the EAST COAST, then you already have a leg-up on this game behind WeBull, & the otherwise natural 3-hours TIME differential for doing this stuff.

PS: By the way, Ms. Reena posted on Orion's that she herself did NOT attempt to play that @INM 'casino table' during today's Pre-M --- despite her being the entire iHub site's very FIRST to post about it.

MORE TO COME*******BUT HAVE TO BE VERY QUICK TO TAKE PROFITS******DUMPING IS OUTRAGEOUS

@INM: Me too, Tim!! (And, I thought I had DISCIPLINED myself --- during the last 3-years, or so --- to immediately JUMP when iHub's Ms. "Reena969" announces in any day's Pre-M, e.g., "XYZP, it's running!")

INM *****EPIC MOVE BUT MISSED IT.

CING: Pretty good, finally, Capt. Tim --- behind my very SLOW-MOVING @TLS stock, which looks like it might run into the Post-M somewhat. (And I almost jumped-on ihub's "Reena969" Pre-M @INM monster pick --- which crashed gloriously in the Open, however. But, anyone COULD have scored 3-times their money in the Pre-M, where @INM hit circa 500% up..)

that is correct******how was trading for you today

What did I say. They are diluting with zero revenue. Short

Indeed, Capt. Tim! (And right now, there goes that TGL, already on Mars; trying to find something about other than TGL's "Request to Withdraw Registration" statement of a few days ago --- i.e., that clever ploy of NOT dumping more stocks to the Market.)

If u haven’t followed this CEO rant and figured out their-moves then day trade it. The move was massively made and then they release an s-1. Again. June 2025 if your read the news. Short answer is-short this with stops till it goes to .35 again in a year. Our desk knows and we know Wainwright. Scammers and unable to make the right call

MONK SAYING**** THE PRICE IS WHAT THE MARKET SAYS**** I OVERLOOKED "SOND" THIS MORNING WITH LESS THAN 50,000 VOLUME AND MISSED IT. HEY, WELCOME, WE LEARN EVERYDAY.


DID U CAUGHT SOME "CINGW" LAST FRIDAY 1000%

CING: Bad day for me, Capt. Tim!! (Wish I NEVER got out of bed today.)

Then there's that scamming @ALZN firm, PR'ing the IDENTICAL (so-called) "news" three times since this Aug. 6th!! (And yet it soars to 600+%!!)

WAKE UP BRO OR TRADING ALREADY. STAY BLESSED AND HAPPY WEEK TRADING

There's not even that many shares to short, perhaps you have the wrong board.

54 MILLION SHORT IN THE LAST TWO SESSIONS..THEY HAVE BEEN BUILDING THEIR POSITIONS, FREAKS THAT SAY SHORTS IN TROUBLE ARE CLUELESS...THEY ARE READY TO PULL THE RUG TO FILL THE GAP

Well they could’ve done it at 3 bucks verse 15 or whatever the filing says

Shorts still nervous who knows where this goes

Reverse split—stock offer-reverse split-stock offer. Like clockwork

Would be awesome

$150 price target. Easy money less than million shares outstanding.

#CING 🔥 this stock having monster run! whats next? $CING

going to fill the gap from 25-40 look at the daily chart and the 200 ema !

Made my year, awesome awesome run $$$$$$$ :)

No revenue , FDA you know how it works
Target $1

How much money in this drug? lol

Monday is interested by with having low available shared. $50 likely possible

Don’t have ya on ignore bro

Congrats! Shorts got shafted, luvn it here lol

Bought 4.75-5.50 sold 12-12.50, oh well still made a sweet amount of wealth $$$$$$
We may reload the dip next week, profits will be taken as you see in after hours folks

CING: Regarding their latest ADHD Patent "news", what this firm has right now does NOT even qualify as an FDA-approved "CANDIDATE" drug. And, if it eventually DOES qualify as such, this firm must then conduct the likely several YEARS of laboratory, animal, & Phase-1, Phase-2, Phase-3 HUMAN trials necessary for consideration by the FDA as an ACTUAL therapeutic treatment for ADHD, or any other mental or Psychiatric afflictions of Mankind.
CANDIDATE DRUGS
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

CING: "NOT" so easy, fellow --- who has me on iHub's "IGNORE" setting. Hey, MONSTER CONGRATS to all who scored big MONEY behind this typical 'DRUG-CANDIDATES-CARNIVAL-SHOW-COMPANY'. However, this CING firm has NOT conducted even a PHASE-1 human trial for their 'Patented' ADHD routine. All they have right now is a "CANDIDATE" drug routine for ADHD --- and nothing else!! I.e., just like the @TSOI & @HALB firms, they squander their time & energy merely seeking 'PATENTS' for whatever, around the Globe!!
https://www.globenewswire.com/news-release/2024/08/15/2930828/0/en/Cingulate-Issued-European-Patent-for-Lead-Asset-CTx-1301-for-the-Treatment-of-ADHD.html
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

CONGRATS BURN THOSE F@CKERS!!!!

Yuppppp. I’m out 3/4 nice check to come home to. $297k. Thank you

CING: Was their now EU-Patented treatment PROVEN to work in Phase-3 Human Trials --- and to what extent, vs. the Placebo & & Standard-of-Care control groups???

Cing 35.00 easy

Oh my

Don’t mess with the professionals. 100m yesterday someone is making a bag load of cash. Unbelievable

Oh geeeeeez